Calabrese et al Moretzsohn LD, Brito EM, Reis MSF, et al. 2002. Assessment of effectiveness of different dosage regimens of Pantoprazole in controlling symptoms and healing esophageal lesions of patients with mild erosive esophagitis. Arch Gastroenterol, 39:123–5. Muller P, Simon B. 1998. The action of proton pump inhibitor pantoprazole against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled double blind comparison. Arzneimittelforshung, 48:482–5. Ollyo JB, Monnier P, Fontolliet C, et al. 1993. The natural history, prevalence and incidence of reﬂux esophagitis. Gullet, 3(Suppl 1):3–10. Pali A, Hungin S, Raghunath A. 1994. Managing gastro-oesophageal reﬂux disease in the older patient. Digestion, 69(suppl 1):17–24. Pilotto A, Franceschi M, Paris F. 2005. Recent advances in the treatment of GERD in the elderly: focus on proton pump inhibitors. Int J Clin Pract, 59:1204–9. Pilotto A, Leandro G, Franceschi M. 2002. Long-term clinical outcome of elderly patients with reﬂux esophagitis: a six-month to three-year follow up study. Am J Ther, 9:295–300. Pilotto A, Leandro G, Franceschi M. 2003. Short and long term therapy for reﬂux esophagitis in the elderly: a multi-centre, placebo-controlled study with pantoprazole. Aliment Pharmacol Ther, 17:1399–406. Prach AT, McGilchrist MM, Murray FE, et al. 1999. Prescription of acid suppressing drugs in relation to endoscopic diagnosis: a record-linkage study. Aliment Pharmacol Ther, 13:397–405. Raghunath AS, Hungin APS. 2004. Long-term prescribing of proton pump inhibitors in primary care: a cross-sectional survey. Gut, 53(suppl. 1): A24. Raghunath AS, Morain CO, MCloughlin RC. 2005. Review article: the long-term use of proton pump inhibitors. Alimentary Pharmacol Ther, 22(suppl 1):55–63. Raiha I, Hietanen E, Sourander L. 1991. Simptoms of gastroesophageal reﬂux disease in elderly people. Age Ageing, 20:365–70. Raiha IJ, Impivaara O, Seppala M, et al. 1992. Prevalence and characteristics of symptomatic gastroesophageal reﬂux in the elderly. J Am Geriatric Soc, 40:1209–11. Regula J, Butruk E. 2006. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroeneterol, 101:1747–55. Richardson P, Havkey CJ, Stack WA. 1998. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs, 56:307–35. Richter JE, Fraga P, Mack M, et al. 2004. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther, 20:567–75. Richter JE. 2000. Gastroesophageal reﬂux disease in the older patient: presentation, treatment and complications. Am J Gastroenterol, 95:368–73. Roberts SJ, Bateman DN. 1995. Prescribing of antiacids and ulcer healing drugs in primary care in the north of England. Aliment Pharmacol Ther, 9:137–43. Rubin GP, Contractor B, Bramble MG. 1995. The use of long term acid- suppression therapy. Br J Clin Pract, 49:119–20. Ryder SD, O’Reilly S, Miller RJ, et al. 1994. Long term acid suppressing treatment in general practice. BMJ, 308:827–30. Sachs G, Shin JM, Besancon M, et al. 1993. The continuing development of gastric acid pump inhibitors. Alimen Pharmacol Ther, 7:4–12. Sandmark S, Carlsson R, Fausa O, et al. 1998. Omeprazole or ranitidine in the treatment of reﬂux esophagitis. Results of a double blind randomized Scandinavian multicenter study. Scand J Gastroenterol, 23:625–32. Scholten T, Dekkers CPM, Schutze K, et al. 2005. On-demand therapy with pantoprazole 20 mg as effective long term management of reﬂux disease in patients with mild GERD: the Orion trial. Digestion, 72:76–85. Shin JM, Sachs G. 2002. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology, 123:1588–97. Singh G, Triadaphilopoulos G. 1999. Epidemiology of NSAID-induced GI complications. J Reumatol, 26(suppl 26):18–24. Stanghellini V, Armstrong D, Monnikes H, et al. 2005. Determination of ReQuest-based symptom thresholds to deﬁne symptom relief in GERD clinical studies. Digestion, 71:145–51. Stupnicki T, Dietrich K, Gonzales Carro P, et al. 2004. Efﬁcacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion, 70:61–9. Stupnicki T, Dietrich K, Gonzales-Carro P, et al. 2003. Efﬁcacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion, 68:198–208. Tsai HH, Chapman R, Shepherd A, et al. 2004. Esomeprazole 20 mg on- demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro- oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther, 20:657–65. Vanderhoff BT, Tahboub RM. 2002. Proton pump inhibitors: an update. Am Fam Physic, 66:273–80. van Zyl J, van Rensburg C, Vieweg W, et al. 2004. Efﬁcacy and safety of Pantoprazole versus Ranitidine in the treatment of Patients with symptomatic gastroesophageal reﬂux disease. Digestion, 70:61–9. Venables TL, Newland RD, Patel AC, et al. 1997a. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophagel reﬂux disease in general practice. Scand J Gastroenterol, 32:965–73. Venables TL, Newland RD, Patel AC, et al. 1997b. Maintenance treatment for gastro-esophageal reﬂux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol, 32:627–32. Vetvik K, Straand J. 2001. Acid-related disease in the population of two Norwegian municipalities—diagnosis and drug therapy. Tidsskr Nor Laegeforen, 121:557–62. Vicari F, Belin J, Marek L, et al. 1998. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reﬂux esophagitis: results of French multicenter double-blind comparative trial. Gastroenterology, 114(suppl 1):A324. 92 Clinical Interventions in Aging 2007:2(1)